# A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency

> **NCT03305016** · PHASE3 · COMPLETED · sponsor: **Ascendis Pharma Endocrinology Division A/S** · enrollment: 146 (actual)

## Conditions studied

- Growth Hormone Deficiency, Pediatric
- Endocrine System Diseases
- Hormone Deficiency
- Pituitary Diseases

## Interventions

- **DRUG:** TransCon hGH

## Key facts

- **NCT ID:** NCT03305016
- **Lead sponsor:** Ascendis Pharma Endocrinology Division A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-13
- **Primary completion:** 2019-03-19
- **Final completion:** 2019-03-19
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2022-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03305016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03305016, "A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03305016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*